{
  "docId": "019de070-2277-75da-968a-7dffc3addc7d",
  "docSlug": "9a22f83671fc7371cae4ff7d98099963",
  "documentTitle": "Fusion Pharmaceuticals | IPO Presentation Deck | 49 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 49,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide illustrates a process flow from the imaging analogue to the clinical outcomes of population enrichment and organ safety assessment.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-2277-75da-968a-7dffc3addc7d/13",
  "deckHref": "/decks/019de070-2277-75da-968a-7dffc3addc7d",
  "deckJsonHref": "/decks/019de070-2277-75da-968a-7dffc3addc7d.json",
  "deckAnchorHref": "/decks/019de070-2277-75da-968a-7dffc3addc7d#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.9,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "diagram",
      "text": "Process flow from In-111 imaging analogue to clinical imaging and dosimetry results.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9337cf4e-ab96-426d-948c-244592d37516",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "list",
      "text": "Imaging analogues of TATs utilize the same targeting molecule and linker\nReplace Ac-225 with imaging isotope, In-111",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8f2697c-176a-47b7-b5da-f40a31821291",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 1,
        "x": 0,
        "y": 0.93
      },
      "kind": "title",
      "text": "Imaging allows assessment of uptake into the targeted tumor and dose to normal organs",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28aedda3-91fd-47e6-b8cf-d6efd1acf64c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Use of Imaging Diagnostics to Enrich Target Populations",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8209405e-84a2-4deb-85b6-b70611a92ff7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 9,
      "beatId": "4c7594b9-88ee-45e3-a687-4c061cad7482",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The deck showcases Fusion Pharmaceuticals' next-generation radiopharmaceuticals and its proprietary platform technology.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}